THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 121 filers reported holding THERAVANCE BIOPHARMA INC in Q2 2023. The put-call ratio across all filers is 0.98 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $145,830 | -16.6% | 16,898 | 0.0% | 0.04% | -13.0% |
Q2 2023 | $174,894 | -50.6% | 16,898 | -48.3% | 0.05% | -48.9% |
Q1 2023 | $354,318 | +0.2% | 32,656 | +3.6% | 0.09% | +25.0% |
Q4 2022 | $353,744 | -40.9% | 31,528 | -46.7% | 0.07% | -17.2% |
Q3 2022 | $599,000 | – | 59,100 | – | 0.09% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Chescapmanager LLC | 1,134,718 | $23,160,000 | 2.47% |
Baupost Group | 8,735,168 | $178,285,000 | 1.42% |
Orbimed Advisors | 6,219,110 | $126,932,000 | 1.19% |
CM Management, LLC | 50,000 | $1,021,000 | 0.76% |
Tekla Capital Management LLC | 456,296 | $9,313,000 | 0.32% |
Rock Springs Capital Management LP | 682,600 | $13,932,000 | 0.30% |
Virtus ETF Advisers LLC | 32,871 | $671,000 | 0.28% |
Cormorant Asset Management, LP | 550,000 | $11,226,000 | 0.25% |
DAFNA Capital Management LLC | 41,165 | $840,000 | 0.20% |
PEREGRINE CAPITAL MANAGEMENT LLC | 484,206 | $9,883,000 | 0.18% |